Bachmann Martin F, El-Turabi Aadil, Fettelschoss-Gabriel Antonia, Vogel Monique
Department of Immunology, RIA, University Hospital Bern, Bern, Switzerland.
Department of BioMedical Research, University of Bern, Bern, Switzerland.
Front Microbiol. 2018 Oct 24;9:2522. doi: 10.3389/fmicb.2018.02522. eCollection 2018.
Allergen-specific T helper type 2 (Th2) responses followed by eosinophilic inflammation of the lung are important causes of allergic asthma. Interleukin-5 (IL-5) is a master regulator of eosinophil differentiation as well as activation. Blocking IL-5 using monoclonal antibodies (mAbs) against IL-5 is a powerful way to improve asthmatic symptoms in patients with an eosinophilic component of the disease. We have previously shown that vaccination against IL-5 can abrogate eosinophilic inflammation of the lung in allergic mice. More recently, we have demonstrated that eosinophil-mediated skin disease in horses with insect bite hypersensitivity can be strongly reduced by vaccination against IL-5. Here we would like to propose the development of a similar vaccine for the treatment of asthma in humans.
过敏原特异性2型辅助性T细胞（Th2）反应继而引发的肺部嗜酸性粒细胞炎症是过敏性哮喘的重要病因。白细胞介素-5（IL-5）是嗜酸性粒细胞分化及激活的主要调节因子。使用抗IL-5单克隆抗体（mAb）阻断IL-5是改善患有嗜酸性粒细胞成分疾病患者哮喘症状的有效方法。我们之前已表明，针对IL-5进行疫苗接种可消除过敏性小鼠肺部的嗜酸性粒细胞炎症。最近，我们证明，针对IL-5进行疫苗接种可大幅减轻马因昆虫叮咬超敏反应而引发的嗜酸性粒细胞介导的皮肤病。在此，我们提议研发一种类似疫苗用于治疗人类哮喘。
